Mental Health of Youths Who Use Puberty Blockers
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.23302 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Clair Kronk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Equity Research, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York. Hauptthemen laut MEDLINE: Puberty Inhibitors, Transgender Persons, Puberty, Precocious, Gender Dysphoria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Puberty blockers are an established, reversible intervention for central precocious puberty in children and gender dysphoria in adolescents. Despite broad clinical support, these treatments are currently politically contested.
Objective
To characterize the mental health of transgender youths prescribed puberty blockers compared with cisgender peers who received these medications for treatment of precocious puberty and with transgender and cisgender youths who did not receive these medications. Design, Setting, and Participants This retrospective cohort study used data from a US nationwide, multipayer claims database from January 2016 to January 2025. Youths aged 10 to 17 years were categorized into 4 cohorts based on gender modality (transgender or cisgender) and prescription of a puberty blocker (yes or no). Main Outcomes and Measures Primary outcomes were International Statistical Classification of Diseases and Related Health Problems, Tenth Revision ( ICD-10 ) diagnoses of mood disorders and suicidal thoughts and behaviors. Inverse probability–weighted generalized estimating equation models were fit to obtain adjusted odds ratios (aORs) and 95% CIs, adjusting for demographics, payer type, region, year, socioeconomic disadvantage, and policy environment indices. In demographics, female gender marker is used to indicate that an F (female) has been applied as a marker for the individual by some entity (eg, a medical professional or government body).
Results
Among 231 783 youths in the analytical sample, 41 472 youths (17.89%) were transgender (median [IQR] age at baseline, 9.00 [7.00-11.00] years; 31 246 with female gender marker [75.34%]) and 190 311 youths (82.11%) were cisgender (median [IQR] age at baseline, 8.00 [6.00-10.00] years; 128 942 with female gender marker [67.75%]). Being transgender was associated with higher odds of mood disorder diagnosis (aOR, 4.42 [95% CI, 4.24-4.60]) and suicidal thoughts and behaviors (aOR, 12.21 [95% CI, 10.69-13.95]) compared with being cisgender. Being prescribed a puberty blocker was associated with higher odds of mood disorder diagnosis (aOR, 2.11 [95% CI, 2.02-2.19]) and suicidal thoughts and behaviors (aOR, 3.04 [95% CI, 2.65-3.49]) compared with no prescription. However, among transgender youths, prescription of a puberty blocker was associated with decreased adjusted odds of mood disorder diagnosis (aOR, 0.52 [95% CI, 0.45-0.60]) and suicidal thoughts and behaviors (aOR, 0.20 [95% CI, 0.14-0.29]). Conclusions and Relevance In this study, transgender youths overall had substantially higher rates of diagnosed mood disorder and suicidal thoughts and behaviors than their cisgender peers, highlighting the need for population-specific interventions. Prescription of a puberty blocker was associated with partial attenuation of this disparity, suggesting mental health benefits associated with this treatment for transgender youth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Health Equity Research, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.
- Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, Connecticut.
- Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
- Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.
- Department of Psychiatry, University of Pennsylvania, Philadelphia.
- Now with Department of Psychiatry, Mid-Atlantic Permanente Medical Group, Upper Marlboro, Maryland.
Zitieren
APA
Kronk, C., Jain, R., Dai, Y., Wolfe, H. L., Hughes, L., Goetz, T. G., Jackson, S. T., Hardy, D. S., Kidd, K., & Reisner, S. L. (2026). Mental Health of Youths Who Use Puberty Blockers. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.23302
Vancouver
Kronk C, Jain R, Dai Y, Wolfe HL, Hughes L, Goetz TG, et al. Mental Health of Youths Who Use Puberty Blockers. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.23302
BibTeX
@article{Kronk2026,
author = {Kronk, Clair and Jain, Rishabh and Dai, Yang and Wolfe, Hill L and Hughes, Landon and Goetz, Teddy G and Jackson, Samuel T and Hardy, Daniel S and Kidd, Kacie and Reisner, Sari L},
title = {Mental Health of Youths Who Use Puberty Blockers},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.23302}
}
EUVIMED